Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|4|E74-E74

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.4, 2015-04, pp. : E74-E74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 755-768

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systemic Mastocytosis

By  

THE JOURNAL OF DERMATOLOGY, Vol. 14, Iss. 5, 1987-10 ,pp. : 483-490

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-02 ,pp. : 88-93

Karger

Access to resources Recommend Favorite

Macrophage Migration Inhibitory Factor Down‐Regulates the RANKL–RANK Signaling Pathway by Activating Lyn Tyrosine Kinase in Mouse Models

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 9, 2014-09 ,pp. : 2482-2493

John Wiley & Sons Inc

Access to resources Recommend Favorite

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

By  

THE JOURNAL OF PATHOLOGY, Vol. 237, Iss. 1, 2015-09 ,pp. : 14-24

John Wiley & Sons Inc

Access to resources Recommend Favorite